GlassScriptPhysician profile
Saima Maqsood
NPI 1629276985
$655.20
in general payments reported to CMS, 2019-2025
15 companies · $152 in 2025
The $152 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $87.34 · 2020: $33.80 · 2021: $20.84 · 2022: $229 · 2023: $62.53 · 2024: $70.36 · 2025: $152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $285.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $284.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $92.80 | 2019-2025 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $82.55 | 2022-2024 | Caplyta |
| Tris Pharma INC | $59.68 | 2022-2025 | Onyda Xr |
| Neurocrine Biosciences, INC. | $53.84 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $51.43 | 2025 | Fanapt, Hetlioz |
| Sunovion Pharmaceuticals INC. | $48.19 | 2019-2020 | |
| Ucb, INC. | $40.73 | 2022-2023 | Cimzia |
| Teva Pharmaceuticals USA, INC. | $37.95 | 2024-2025 | Austedo Xr, Austedo Xr |
| Janssen Pharmaceuticals, INC | $36.69 | 2025 | Invega Sustenna, Spravato |
| Otsuka America Pharmaceutical, INC. | $35.74 | 2022 | |
| Corium, LLC | $33.83 | 2024 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $33.42 | 2019-2022 | |
| Novo Nordisk INC | $18.00 | 2023 | Rybelsus, Ozempic |
| Neuronetics, INC. | $15.35 | 2020 | |
| Lundbeck LLC | $15.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saima Maqsood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.